Provention Bio, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Provention Bio, Inc. was a biopharmaceutical firm dedicated to the advancement of therapies aimed at intercepting and preventing immune-mediated conditions. The company's significant contribution was TZIELD (teplizumab-mzwv), which became the first and only approved disease-modifying treatment in the U.S. for delaying the onset of Stage 3 type 1 diabetes in at-risk individuals aged eight years and older with Stage 2 of the disease. In April 2023, Sanofi completed its acquisition of Provention Bio for approximately $2.9 billion, integrating TZIELD into Sanofi's portfolio of general medicines. This strategic move enhanced Sanofi's presence in immune-mediated diseases and diabetes, leveraging Provention Bio's innovative therapy. Sanofi intends to utilize its global capabilities to maximize TZIELD's potential to reach more patients. Prior to the acquisition, Provention Bio's pipeline also included other candidates targeting various immune-mediated diseases. Originally established in 2016, Provention Bio was headquartered in Red Bank, New Jersey.
Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.
The 5 Best- and Worst-Performing Mid-Cap Stocks in March 2023
PROVENTION BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Provention Bio, Inc. - PRVB
Why Provention Bio Stock Skyrocketed 256% This Week
Provention (PRVB) Skyrockets 260% on Buyout Offer From Sanofi
SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Provention Bio, Inc. - PRVB
This biopharma stock jumped over 250% on Monday: what happened?
Monday Merger Mania Just Made These 2 Biotech Stocks Big Winners
Shareholder Alert: Ademi LLP investigates whether Provention Bio, Inc. has obtained a Fair Price in its transaction with Sanofi
Regional banks pace decliners, as biotech deals lift Seagen and Provention Bio
Provention Bio shares soar after Sanofi agrees to buy company in $2.9B cash deal
PRVB STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Provention Bio, Inc. Is Fair to Shareholders
Why Is Provention Bio (PRVB) Stock Up 263% Today?
Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call
Sanofi To Buy Provention Bio In $2.9 Billion Deal (SNY) (PRVB)
Sanofi to buy Provention Bio in deal worth $2.9 billion
Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)
Provention Bio Announces the Grant of Inducement Awards
Provention Bio to Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
Provention Bio: Good Prospects In Type 1 Diabetes, But Patent Protection Is A Worry